AbCellera Biologics
AbCellera Biologics' revenue rose 160.6% to $75 million in fiscal 2025. Its operating margin was −289.0%, up from −1,091.7% a year earlier. Free cash flow was −$174 million. The diluted share count rose 1.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What AbCellera Biologics does
AbCellera is a clinical-stage biotechnology company that discovers and develops antibody medicines. It built a platform for finding antibodies for hard-to-reach targets, and it used that platform for partners' drug programs for years. It has now shifted toward building its own pipeline of drug candidates.
Its two lead candidates are in early clinical trials in Canada. One is for hot flashes linked to menopause, and the other is for atopic dermatitis and other inflammatory conditions. Two more candidates are in preparation for trials, and it has many earlier discovery programs.
AbCellera does not sell an approved drug. It says it expects losses and negative operating cash flow in the near to medium term, and expects future revenue from out-licensing programs, milestone payments and royalties. It also opened its own clinical manufacturing facility in Vancouver.
Its biggest risks, as it describes them
- Losses so far and no approved drug, so profits depend on its own candidates succeeding.
- Drug development is uncertain, and its candidates may fail in clinical trials.
- Partners may fail to meet their obligations or milestones, which would hurt its revenue.
- Competitors may develop safer, more effective or cheaper drugs.
- Revenue has varied a lot from period to period.
Income statement
From fiscal 2020 to 2022, earnings per share grew 5.4% a year and net income 15.5% a year, as new shares raised the share count by 20% and diluted each share's earnings. AbCellera Biologics then lost money in fiscal 2023, 2024 and 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 476 | 386 | 761 | 626 | 534 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 7.7x | 8.7x | 7.3x | 9.8x | 11.3x |
| Quick ratio | 7.7x | 8.7x | 7.3x | 9.8x | 11.2x |
Cash flow
Projections
Project AbCellera Biologics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 4 insiders bought $2.7 million of AbCellera Biologics shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 24, 2026 | Michael R HaydenDirector | Bought | 53,613 | $10.64 | $570,442 | Form 4 |
| Aug 18, 2026 | John S. MontalbanoDirector | Bought | 10,000 | $11.03 | $110,300 | Form 4 |
| Aug 14, 2026 | Andrew BoothChief Financial Officer | Bought | 37,200 | $10.32 | $383,904 | Form 4 |
| Aug 12, 2026 | Michael R HaydenDirector | Bought | 46,387 | $10.37 | $481,033 | Form 4 |
| May 14, 2026 | John S. MontalbanoDirector | Bought | 20,000 | $4.77 | $95,400 | Form 4 |
| Feb 27, 2026 | Andrew BoothChief Financial Officer | Bought | 42,600 | $3.42 | $145,692 | Form 4 |
| Feb 27, 2026 | Thermopylae Holdings Ltd.10% owner | Bought | 38,000 | $3.44 | $130,720 | Form 4 |
| Feb 26, 2026 | Thermopylae Holdings Ltd.10% owner | Bought | 177,457 | $3.27 | $580,284 | Form 4 |
| Nov 26, 2025 | John S. MontalbanoDirector | Bought | 50,000 | $3.57 | $178,500 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −409.9% | −672.6% | −71.1% |
| Altman Z'' | 6.46 | 5.62 | 4.67 |
| Accruals ratio | −6.8% | −3.8% | −1.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Pass | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Fail | Pass |
| F-score | — | — | — |
Compare
Put AbCellera Biologics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| AbCellera Biologics | FY25 | 160.6% | −289.0% | −231.7% | — | — | — | |
| Autolus Therapeutics | FY25 | 644.9% | −358.9% | −401.4% | — | — | 3 | Compare |
| Recursion Pharmaceuticals | FY25 | 26.9% | −867.9% | −506.5% | −117.2% | — | 4 | Compare |
| CytomX Therapeutics | FY25 | −44.8% | −29.4% | −99.5% | — | — | — | Compare |
| Cellectis | FY25 | 75.8% | −45.3% | −57.2% | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 12 | 233 | 375 | 485 | 38 | 29 | 75 |
| Revenue growth | — | 1,907.9% | 60.9% | 29.4% | −92.2% | −24.2% | 160.6% |
| Gross profit | — | — | — | — | — | — | — |
| Research and development | 10 | 29 | 62 | 108 | 176 | 167 | 187 |
| Operating income | −4 | 156 | 204 | 216 | −237 | −315 | −217 |
| Net income | −2 | 119 | 154 | 158 | −146 | −163 | −146 |
| Diluted EPS (US$) | −0.01 | 0.45 | 0.48 | 0.50 | −0.51 | −0.55 | −0.49 |
| Diluted shares (millions) | 151 | 263 | 318 | 315 | 289 | 294 | 299 |
| Cash flow | |||||||
| Cash from operations | 3 | 23 | 245 | 277 | −44 | −109 | −131 |
| Capital expenditure | 4 | 10 | 58 | 71 | 77 | 78 | 43 |
| Free cash flow | −1 | 13 | 186 | 207 | −121 | −187 | −174 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 88 | 12 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 8 | 31 | 50 | 64 | 68 | 56 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | — | 594 | 476 | 386 | 761 | 626 | 534 |
| Debt incl. finance leases | — | — | — | — | — | — | — |
| Total assets | — | 1,006 | 1,319 | 1,541 | 1,488 | 1,361 | 1,357 |
| Total liabilities | — | 175 | 293 | 308 | 336 | 304 | 390 |
| Shareholders' equity | 10 | 830 | 1,026 | 1,233 | 1,152 | 1,056 | 967 |
| Margins and ratios | |||||||
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | −35.5% | 66.9% | 54.5% | 44.6% | −623.8% | −1,091.7% | −289.0% |
| Net margin | −19.0% | 51.0% | 40.9% | 32.7% | −385.0% | −564.8% | −194.9% |
| Free cash flow margin | −11.2% | 5.6% | 49.6% | 42.6% | −317.8% | −648.4% | −231.7% |
| Rule of 40 (growth + FCF margin) | — | 1,913.5% | 110.5% | 72.0% | −409.9% | −672.6% | −71.1% |
| Return on capital | — | — | — | — | — | — | — |
| Return on equity | — | — | 16.5% | 14.0% | −12.3% | −14.8% | −14.5% |
| Return on assets | — | — | 13.2% | 11.1% | −9.7% | −11.4% | −10.8% |
| Net debt to EBITDA | — | — | — | — | — | — | — |